Abstract
Amyotrophic lateral sclerosis (ALS) is a debilitating and ultimately fatal indication that is the most prevalent adult-onset motoneuron disorder. ALS imparts tremendous suffering upon patients and caregivers alike. Exciting new insight has been obtained as to the etiology and initiation of the disease during the past decade, particularly affecting the larger, sporadic patient population. An important new discovery is the involvement of the TAR DNA binding protein (TDP-43) based upon genetic evidence and the presence of the cytosolic ubiquitinylated TDP-43 aggregates found during post-mortem analysis of damaged motoneuron in the spinal cord of ALS patients. Superoxide dismutase (SOD1) continues to be of interest for the ∼20% of the familial ALS patients who have the inherited form of the disease (∼15% of the total), but SOD1 does not appear to be as relevant as was once imagined for the sporadic patient population. We can now target specific biochemical pathways and deficits via traditional drug discovery efforts and may thus be able to achieve more effective therapeutic relief for patients who suffer from this disease. In this review we present a comprehensive discussion of current molecular targets and pathways that are of interest to small molecule drug discovery efforts for the treatment of ALS.
Keywords: Amyotrophic lateral sclerosis, ALS, neurodegeneration, heat shock, TDP-43, drug targets
Current Pharmaceutical Design
Title: Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Volume: 16 Issue: 18
Author(s): Aaron C. Pawlyk, Joel A. Cassel and Allen B. Reitz
Affiliation:
Keywords: Amyotrophic lateral sclerosis, ALS, neurodegeneration, heat shock, TDP-43, drug targets
Abstract: Amyotrophic lateral sclerosis (ALS) is a debilitating and ultimately fatal indication that is the most prevalent adult-onset motoneuron disorder. ALS imparts tremendous suffering upon patients and caregivers alike. Exciting new insight has been obtained as to the etiology and initiation of the disease during the past decade, particularly affecting the larger, sporadic patient population. An important new discovery is the involvement of the TAR DNA binding protein (TDP-43) based upon genetic evidence and the presence of the cytosolic ubiquitinylated TDP-43 aggregates found during post-mortem analysis of damaged motoneuron in the spinal cord of ALS patients. Superoxide dismutase (SOD1) continues to be of interest for the ∼20% of the familial ALS patients who have the inherited form of the disease (∼15% of the total), but SOD1 does not appear to be as relevant as was once imagined for the sporadic patient population. We can now target specific biochemical pathways and deficits via traditional drug discovery efforts and may thus be able to achieve more effective therapeutic relief for patients who suffer from this disease. In this review we present a comprehensive discussion of current molecular targets and pathways that are of interest to small molecule drug discovery efforts for the treatment of ALS.
Export Options
About this article
Cite this article as:
C. Pawlyk Aaron, A. Cassel Joel and B. Reitz Allen, Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis, Current Pharmaceutical Design 2010; 16 (18) . https://dx.doi.org/10.2174/138161210791293024
DOI https://dx.doi.org/10.2174/138161210791293024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The beneficial effect of Cape gooseberry juice on carbon tetrachloride-induced neuronal damage
CNS & Neurological Disorders - Drug Targets Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNAs: Newcomers into the ALS Picture
CNS & Neurological Disorders - Drug Targets A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry